Prolonged Daily Temozolomide for Low-Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

December 31, 2006

Study Completion Date

September 30, 2009

Conditions
GliomaAstrocytomaOligodendroglioma
Interventions
DRUG

Temozolomide

Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

collaborator

Brigham and Women's Hospital

OTHER

collaborator

University of Virginia

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00165360 - Prolonged Daily Temozolomide for Low-Grade Glioma | Biotech Hunter | Biotech Hunter